US/UK/Canada

Share

Contacts

  • Petter Bäckgren

    CEO


  • Mikael Wester

    Marketing Director


    +4670-721 12 80
    http://www.bioservo.com

    • Links

    Pick a time period -
    Tags ( Active)

    Bioservo Collaborates with Limb Lab to Expand Accessibility of Carbonhand[®] Across the United States

    Bioservo, a global pioneer in wearable medical robotics that revolutionizes assistive care with its innovative “State of the art” technology, proudly announces a plan to collaborate strategically with Limb Lab, a best-in-class orthotics and prosthetics provider. This collaboration aims to bring the groundbreaking Carbonhand® technology to patients across the United States. Limb Lab, an independently-owned and -operated prosthetic and orthotic company, is known for its innovative and personalized approaches to supporting individuals with limb difference and other functional needs.

    Carbonhand Now Available on the VA Federal Supply Schedule (FSS)

    Bioservo is excited to announce that our groundbreaking assistive device, Carbonhand, is now available to veterans across the United States through the Department of Veteran Affairs (VA) Federal Supply Schedule (FSS) and GSA Advantage. This significantly enhances access to Carbonhand for veterans with impaired hand function, offering them a valuable tool for regaining independence and improving their quality of life. The U.S. Department of Veteran Affairs officially approved the award to our partner, Affirmative Solutions, LLC, a Service-Disabled Veteran-Owned Small Business (

    EXXOMOVE Takes Over the Exclusive Representation of the Hand Orthosis Carbonhand in Germany

    Bioservo AB, a global leader in wearable muscle-strengthening systems, is proud to announce a significant expansion of our partnership with EXXOMOVE UG, our longstanding distribution partner in Germany. Effective October 1, 2024, EXXOMOVE will take over as the exclusive distributor of our innovative hand orthosis Carbonhand in Germany, further enhancing the accessibility of this life-changing technology to patients across the country. This strategic collaboration reflects our shared commitment to making Carbonhand available to a larger segment of the German population. In Germany,

    Greater Independence through Added Grip Strength

    Carbonhand, the revolutionary Carbonhand grip-enhancing glove, is now available to everyone in the US. Previously exclusive to US veterans, this innovative assistive device is now accessible to all through our Self-Pay service, offering a revolutionary solution for individuals with reduced grip strength. Carbonhand has already made a significant impact on the lives of veterans by restoring their ability to perform daily activities independently. With its national availability, more people can now experience the enhanced quality of life that Carbonhand provides. Unlock Your

    Skelex acquires the rights for Ironhand from Bioservo

    On June 17, Bioservo AB and Skelex BV signed an agreement on the acquisition of rights for Ironhand. Through this agreement, Skelex takes over the rights to develop and sell Ironhand and expands its portfolio of exoskeletons for the industrial market. Bioservo will fully focus on the life science market and continue to develop and sell Carbonhand.Through this partnership, Skelex is granted global exclusive distribution rights to the existing Ironhand product and a license to the Bioservo technology for developing, manufacturing, and selling new products based on the technology. Skelex also

    Study shows improved hand function using Carbonhand

    Today, a study on Improved physical function using a power-enhancing glove in persons with Inclusion Body Myositis was presented at the Global Conference on Myositis in Pittsburgh, USA. The preliminary results show increased hand function and improved physical function for people with impaired hand function during use of Carbonhand. Inclusion body myositis (IBM) is an autoimmune disease that primarily affects skeletal muscles with reduced muscle strength and endurance as characteristic symptoms. People with IBM experience challenges in many areas of their lives. Gripping and

    Bioservo to be delisted from Nasdaq First North

    Nasdaq has decided to approve Bioservo Technologies' application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024. For more information, please contactLawyer Olov Kling, liquidator, Konrad Advokater ABphone: +46 70 210 13 79olov.kling@konradadvokater.se Mikael Wester, Marketing Director, Bioservo Technologies ABphone: +468 21 17 10mikael.wester@bioservo.com  About Bioservo TechnologiesBioservo Technologies AB (publ) is a world leading

    Liquidator appointed in Bioservo

    The Companies Registration Office has on 18 December 2023 registered Bioservo Technologies’ (”Bioservo”) decision on voluntary liquidation and in accordance with the resolution of the extraordinary general meeting on the 14 December 2023 regarding voluntary liquidation under Chapter 25, Section 3 of the Companies Act, appointed Olov Kling, lawyer at Advokatfirman Lindahl as liquidator. The decision entails that the liquidator replaces the board and the managing director and is assigned to carry out the liquidation. The liquidator will shortly send an application for summons to unknown

    Bioservo applies for delisting from Nasdaq First North

    At the extraordinary general meeting held in Bioservo Technologies (BIOS) (the “Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator. Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press

    Bulletin from the extraordinary general meeting in Bioservo Technologies

    An extraordinary general meeting was held in Bioservo Technologies AB (publ), below the “Company", on December 14, 2023. At the meeting, it was resolved that the Company should enter into voluntary liquidation. The decision was unanimous. Decision on voluntary liquidation The extra general meeting adopted the proposal from the board of directors and thus resolved that the Company should enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act.  Liquidation dateThe resolution regarding liquidation will take effect from the date when the

    Notice of extraordinary general meeting in Bioservo technologies ab (publ)

    The shareholders in Bioservo Technologies AB (publ) reg. no. 556650-7264 (the “Company”) are hereby convened to the extraordinary general meeting on Thursday 14 December 2023 at 10.00 at the Company´s office on Torshamnsgatan 35, Kista. Right to participate in the general meetingShareholders who wish to participate at the extraordinary general meeting shall: · on Wednesday 6 December 2023 (the record date), be registered in the share register kept by Euroclear Sweden AB in their own names (not nominee-registered shares), and · notify the Company of his or her intention to

    Bioservo is proposed to enter into liquidation

    Today, Bioservo Technologies (BIOS), a company within wearable grip-strengthening systems for people in need of extra strength and endurance, announces that the board of directors will propose to the shareholders that the company enters into voluntary liquidation.Despite significant interest in Bioservo’s technology from companies in the industrial segment and numerous evaluation projects, the sales of Ironhand[®] have not met expectations, and the willingness to invest in the company's technology in the near future is deemed low. In the Life Science sector, the sales of Carbonhand[®] have

    Bioservo Technologies AB Interim Report January – September 2023

    July-September in figures · Net sales of 4.2 MSEK (1.9) · EBITDA of -9.3 MSEK (-9.9) · EBIT of -9.8 MSEK (-10.7) · Earnings for the period amounted to -9.8 MSEK (-10.7) · Earnings per share before and after dilution amounted to SEK -0.12 (-0.56) · Cash flow from operating activities for the period amounted to – 15.2 MSEK (-15.0) January-September in figures · Net sales of 10.0 MSEK (8.4) · EBITDA of -29.6 MSEK (-31.6) · EBIT of -31.0 MSEK (-34.6) · Earnings for the period amounted to -31.1 MSEK (-34.6) · Earnings per share before and after dilution

    Carbonhand sales doubled in Norway

    Sales of the strength-enhancing glove Carbonhand® have taken off in the Norwegian market. In Norway, Carbonhand is sold through the distributor Cypromed, and so far this year they have ordered twice as many Carbonhand to Norway compared to the same period last year. In Norway, Carbonhand has been prescribed as a medical device through the public reimbursement system for several years. Through the public reimbursement system, Carbonhand is prescribed both as an assistive device for use in the home and as an aid to return to work. The new version of Carbonhand launched this year has

    Carbonhand sales take off in Europe's largest market

    Sales of the strength-enhancing glove Carbonhand[®] have taken off in the German market, where it is estimated that over one million people would be helped by Carbonhand. So far this year, more than four times as many Carbonhand systems have been ordered for Germany compared to the same period last year. Germany is Europe's largest market in terms of population and over 8.7 million people have disabilities of the types Carbonhand is designed for. External analyses show that, conservatively, over 1 million of these people could be helped by Carbonhand to cope better with everyday

    Bioservo is evaluating potential Strategic Alternatives to accelerate commercialization

    Bioservo Technologies (BIOS), a world-leading company in providing sophisticated soft muscle strengthening systems for people in need of extra strength and endurance, today announces that its Board of Directors is evaluating potential strategic alternatives to accelerate commercialization and enhance shareholder value.The Board has established a Special Committee composed of Management team members and members of the Board to evaluate a broad range of potential options, including the sale of part or all of the company, recapitalization, or other partnership opportunities, among other

    Bioservo strengthens focus on Market Access and clinical evidence by appointing Annika Rydgård to the management team

    In the commercialization phase Bioservo is in, clinical evidence is becoming increasingly important, and questions regarding market access in selected markets are of the utmost importance. The company's management team is therefore strengthened with Annika Rydgård, responsible for clinical projects and Market Access. Bioservo has registered the strength-enhancing glove Carbonhand as an assistive medical device in Europe, Australia, and the United States. Bioservo and the sales organizations in each market are working with high intensity to obtain market access and reimbursement

    Carbonhand is available for Veterans in the US

    Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function.[Carbonhand hjlper till i vardagen] Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle,

    Bioservo Technologies AB Interim Report January – June 2023

    April-June in figures · Net sales of 1.2 MSEK (3.6) · EBITDA of -11.4 MSEK (-11.0) · EBIT of -11.9 MSEK (-11.8) · Earnings for the period amounted to -11.9 MSEK (-11.8) · Earnings per share before and after dilution amounted to SEK -0.42 (-0.62) · Cash flow from operating activities for the period amounted to – 9.5 MSEK (-9.8) January-June in figures · Net sales of 5.8 MSEK (6.5) · EBITDA of -20.3 MSEK (-21.8) · EBIT of -21.3 MSEK (-23.9) · Earnings for the period amounted to -21.3 MSEK (-23.9) · Earnings per share before and after dilution amounted

    Carbonhand available in the US through Veterans Healthcare Supply Solutions

    Bioservo signs a wholesale distributor agreement with Veterans Healthcare Supply Solutions for sales of Carbonhand in the US. The initial intent of the agreement is to make Carbonhand available for Veterans Administration Facilities (VA) and Department of Defense Healthcare Facilities (DoD). The agreement can also be expanded to include other customer segments. Veterans Healthcare Supply Solutions (VHSS) has over 30 years of healthcare distribution management experience and represents leading manufacturers to federal government agencies. Established in 2010, VHSS has been a

    Bioservo receives order for 25 Ironhand systems

    Bioservo Technologies receives an order for 25 Ironhand systems at an order value of 1.2 MSEK from Rhino Tool House for sale on the US market. The successful implementation of more than 60 Ironhand systems at the Waupaca Foundry, which has resulted in a significant reduction in hand injuries, has generated increased interest among companies in the foundry and other grip-intensive industries. To meet this increased interest, Rhino Tool House is placing an order for 25 Ironhand systems for delivery in the third quarter. For more information, please contactPetter Bäckgren, CEO,

    Michael Forss new CFO for Bioservo Technologies

    Bioservo Technologies AB (publ) (Nasdaq First North: BIOS) today announces that the company has contracted Michael Forss as new interim CFO and member of the management team. Michael succeeds Madeleine Börjesson as CFO and will take up the position on July 7, 2023.Michael has a background as an auditor and partner at EY with long and valuable experience of public companies in an international environment. Since 2019, Michael works in his own consulting company with advice in financial accounting, reporting and business management. Bioservo would like to take the opportunity to thank

    Bioservo announces final outcome of the Rights Issue

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION.Bioservo Technologies AB ("Bioservo" or "the Company") has today announced the final outcome of the rights issue of units consisting of shares and warrants of series TO3, where the subscription period ended on June 9, 2023 ("the Rights Issue"). The final

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media